Results 1–20 of 82 for orkambi

Written Answers — Department of Health and Social Care: Orkambi (19 Sep 2018)

Lord Pearson of Rannoch: To ask Her Majesty's Government whether they will invite the NHS and the National Institute for Health and Care Excellence to re-consider their decision not to offer Orkambi to cystic fibrosis sufferers in England and Wales.

Written Answers — Department of Health and Social Care: Orkambi (14 Sep 2018)

Luke Hall: To ask the Secretary of State for Health and Social Care, what recent steps the Government has taken to ensure that (a) negotiations between Vertex Pharmaceuticals and NHS England on access to Orkambi for people with cystic fibrosis proceed without further delay and (b) an agreement is reached between the two parties.

Written Answers — Department of Health and Social Care: Orkambi (10 Sep 2018)

Stephen Hepburn: To ask the Secretary of State for Health and Social Care, with reference to the Adjournment debate of 17 July 2018 on Access to Orkambi, Official Report, columns 377-386, if he will take steps to keep hon. Members updated over the summer recess in the event that any progress is made between Vertex and NHS England on making the drug Orkambi available on the NHS for people with Cystic Fibrosis.

Written Answers — Department of Health and Social Care: Cystic Fibrosis: Drugs (4 Sep 2018)

Ivan Lewis: To ask the Secretary of State for Health and Social Care, pursuant to the Adjournment debate of 17 July 2018 on Access to Orkambi, Official Report, cols 377-386, what steps he is taking to (a) facilitate and (b) participate as appropriate in a meeting between the chief executives of NHS England and of Vertex to discuss patient access to lumacaftor-ivacaftor and other medicines for cystic fibrosis.

Written Answers — Department of Health and Social Care: Orkambi (25 Jul 2018)

Ben Bradley: To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) Vertex and (b) NHS England on access to Orkambi on the NHS.

Health and Social Care: Artificial Intelligence (24 Jul 2018)

Ian Austin: ...just artificial intelligence. The development of other life sciences and new technologies can have a massive effect on improving people’s healthcare, such as the development of treatments like Orkambi for people with cystic fibrosis. Will the Secretary of State make it an important priority to cut through the impasse between NHS England and the manufacturer, Vertex, so that people...

Written Answers — Department of Health and Social Care: Orkambi (20 Jul 2018)

Luke Hall: To ask the Secretary of State for Health and Social Care what plans he has to ensure his Department continues to engage and meet with NHS England and Vertex to discuss access to Orkambi.

Written Answers — Department of Health and Social Care: Orkambi (20 Jul 2018)

Luke Hall: To ask the Secretary of State for Health and Social Care, whether ensuring access to Orkambi for people with cystic fibrosis is a priority for his Department.

Written Answers — Department of Health and Social Care: Orkambi (20 Jul 2018)

Luke Hall: To ask the Secretary of State for Health and Social Care, whether a date has been set for the next meeting between NHS England and Vertex to discuss access to the drug Orkambi.

Written Answers — Department of Health and Social Care: Orkambi (20 Jul 2018)

Luke Hall: To ask the Secretary of State for Health and Social Care, what his Department's policy is on Vertex (a) waiving its confidentiality clause on the negotiations around NHS access to the drug Orkambi and (b) disclosing details of its offer to NHS England.

Written Answers — Department of Health and Social Care: Orkambi (19 Jul 2018)

Jeff Smith: To ask the Secretary of State for Health and Social Care, whether he plans to intervene in negotiations between NHS England and pharmaceutical company Vertex on the provision of Orkambi to Cystic Fibrosis patients on the NHS.

Access to Orkambi (17 Jul 2018)

Steve Brine: ...have it. Once more, we have heard hon. Members make compassionate—that is a very good word—pleas urging an immediate resolution in the ongoing discussions between NHS England and Vertex to make Orkambi available on the NHS in England. To the hon. Member for North Down (Lady Hermon), who raised this in an intervention, I say that, absolutely, I will make sure my officials are...

Written Answers — Department of Health and Social Care: Orkambi (11 Jul 2018)

Bill Wiggin: To ask the Secretary of State for Health and Social Care, how many times NHS England has met Vertex to discuss Orkambi; and whether any steps have been taken as a result of those meetings.

Written Answers — Department of Health and Social Care: Orkambi (9 Jul 2018)

Stephen Morgan: ...of 16 May 2018, Official Report, column 276, whether officials of his Department have met with the Prime Minister to discuss negotiations between NHS England and Vertex on the supply of the drug Orkambi.

Written Answers — Department of Health and Social Care: Rare Diseases: Drugs (28 Jun 2018)

Anneliese Dodds: To ask the Secretary of State for Health and Social Care, what assessment he has made of whether NICE's guidance on the drug Orkambi supports his Department's approach of ensuring that NICE appropriately funds new, targeted technologies for the treatment of rare diseases.

Written Answers — Department of Health and Social Care: Orkambi (27 Jun 2018)

Anne Marie Morris: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 April 2018 to Question 135633, on Orkambi, whether his Department has also written to NHS England in similar terms to encourage them to treat negotiations with urgency.

Phenylketonuria: Treatment and Support — [Mr Laurence Robertson in the Chair] (26 Jun 2018)

Paul Masterton: .... We have an odd approach to cost-effectiveness when looking at medicines in this country that I think we need to reassess. That is not only true for Kuvan—we have seen it when talking about Orkambi and for various other issues. I completely agree with the decision of the NSPKU to apply for Kuvan to be placed in the ultra-orphan stream due to the rareness of the condition and the...

Scottish Parliament: Access to Medicines (20 Jun 2018)

Anas Sarwar: ...as it is not considered cost effective, despite it being recognised as clinically effective. I ask again: what cost life? The other drug referred to in our motion is the life-prolonging cystic fibrosis drug Orkambi. It slows the decline in lung function—the main cause of death in cystic fibrosis—by 42 per cent. Orkambi also cuts the number of infections that require...

Scottish Parliament: Decision Time (20 Jun 2018)

..., as a matter of urgency, to bring NHS National Services Scotland, the Scottish Medicines Consortium and the relevant pharmaceutical companies together to deliver access to the life-prolonging medicines, Perjeta and Orkambi, for patients in Scotland who need them; notes the commitment that was made by the Scottish Government in December 2016, following the Review of Access to New Medicines...


1 2 3 4 5 > >>

Create an alert

Did you find what you were looking for?

Advanced search

Find this exact word or phrase

You can also do this from the main search box by putting exact words in quotes: like "cycling" or "hutton report"

By default, we show words related to your search term, like “cycle” and “cycles” in a search for cycling. Putting the word in quotes, like "cycling", will stop this.

Excluding these words

You can also do this from the main search box by putting a minus sign before words you don’t want: like hunting -fox

We also support a bunch of boolean search modifiers, like AND and NEAR, for precise searching.

Date range

to

You can give a start date, an end date, or both to restrict results to a particular date range. A missing end date implies the current date, and a missing start date implies the oldest date we have in the system. Dates can be entered in any format you wish, e.g. 3rd March 2007 or 17/10/1989

Person

Enter a name here to restrict results to contributions only by that person.

Section

Restrict results to a particular parliament or assembly that we cover (e.g. the Scottish Parliament), or a particular type of data within an institution, such as Commons Written Answers.

Column

If you know the actual Hansard column number of the information you are interested in (perhaps you’re looking up a paper reference), you can restrict results to that; you can also use column:123 in the main search box.